SI-BONE (SIBN) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to CyBone's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Saqib Iqbal, Vice President, FP and A and Investor Relations at CyBone for a few introducto ...

Financial Data and Key Metrics Changes - Q1 revenue grew 18% year over year to $55.8 million, marking the thirteenth consecutive quarter of exceeding guidance [14][23] - Gross margin improved to 72.1%, a 170 basis point increase year over year [14][26] - Operating income for Q1 was $39,000, an improvement of $1.4 million year over year [28] - Adjusted EBITDA for Q1 was $1 million, improving by $1.4 million year over year [28] Business Line Data and Key Metrics Changes - Record sales in the Medical segment, particularly in MedSpa and plastic surgery, with strong performance in primary therapy [14][24] - Payments revenue continues to grow at more than twice the rate of total revenue, contributing positively to the business [25][82] - Retention metrics remained stable with Net Revenue Retention (NRR) at 98% and Gross Revenue Retention (GRR) at 91% [25] Market Data and Key Metrics Changes - The acquisition of TrueLark expands the addressable market to over $10 billion in the U.S. [7][19] - New integrations launched in Q1 increased the integrated market by approximately 60,000 locations [15] Company Strategy and Development Direction - The acquisition of TrueLark is aimed at enhancing the product roadmap and expanding market opportunities [12][20] - Focus on automating workflows and improving patient engagement through technology [8][12] - Continued investment in R&D and sales/marketing to drive growth and customer acquisition [21][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business amid economic challenges, with no degradation in lead flow or pipeline [50] - Anticipated core business growth in 2025 to outpace 2024, despite a tough year-over-year revenue comparison in Q2 [30][31] - The company remains focused on revenue growth, operational efficiency, and maintaining positive free cash flow [32] Other Important Information - The company ended Q1 with $98.2 million in cash and short-term investments, with plans to use $25 million for the TrueLark acquisition [28] - The acquisition is expected to close in Q2 2025, with performance-based equity awards tied to revenue milestones [19][21] Q&A Session Summary Question: Incremental value of TrueLark to existing bundles - Management highlighted joint customers and the revenue-driving potential of TrueLark, emphasizing its automation capabilities [36][37] Question: Specialty medical growth and hiring plans - Management confirmed strong Q1 performance in specialty medical and anticipated further growth in the back half of the year due to increased sales capacity [40][41] Question: TrueLark's pricing model and monetization opportunities - TrueLark's product is primarily sold on a per-location or per-contract basis, with opportunities for reevaluation of pricing strategies [45][46] Question: Resilience of the pipeline amid economic challenges - Management reported no degradation in pipeline metrics and expressed optimism about the integration of TrueLark enhancing their market position [49][50] Question: Competitive landscape and AI opportunity - Management noted a clear vision for their product roadmap and highlighted TrueLark's established customer base and proven ROI as competitive advantages [55][56] Question: Vertical penetration and economic sensitivity - Management indicated less than 15% penetration across all verticals, with dental being the most penetrated and specialty medical the least [68][71] Question: Customer acquisition cost and go-to-market strategy - Management confirmed ongoing efforts to refine the go-to-market strategy to reduce customer acquisition costs and increase sales velocity [75][76] Question: Payment solution attach rate - Management noted that the payment solution currently makes up less than 10% of revenue but is growing faster than overall revenue [80][81]

Matson (MATX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 you for standing by and welcome to Matson's First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Justin Schoenberg, Investor Relations and Corporate Development at Matson. Please ...

Vertex Pharmaceuticals (VRTX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Susie Lisa - SVP - Investor RelationsReshma Kewalramani - CEO, President & DirectorStuart Arbuckle - EVP & COODuncan McKechnie - SVP - North America Commercial OperationsCharles Wagner - EVP & CFOGeoff Meacham - Managing DirectorMichael Yee - Managing DirectorLiisa Bayko - Managing DirectorDavid Risinger - Senior Managing Director, BiopharmaGena Wang - MD - Biotech Equity Research Conference Call Participants J ...

Syndax Pharmaceuticals (SNDX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the Syndax First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Clary, Head of Investor Relations at Syndax Pharmaceuticals. Speaker1 Great. Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's first quarter twenty twenty five financial and operating re ...

ThredUp (TDUP) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the ThredUP First Quarter twenty twenty five Earnings Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Monday, May fifth of twenty twenty five. I would now like to turn the conference over to Lauren Fresh. Please go ahead. Speaker1 Good afternoon, everyone, and tha ...

Artivion (AORT) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentPatrick Mackin - Chairman , President & CEOLance Berry - Executive VP & CFOJohn McAulay - AVPSuraj Kalia - Managing DirectorDaniel Stauder - Director - Equity ResearchJeffrey Cohen - MD - Equity Research Conference Call Participants Frank Takkinen - Senior Research AnalystMichael Matson - Senior Analyst Operator Greetings. Welcome to our Ativian's First Quarter twenty twenty five Financ ...

Financial Data and Key Metrics Changes - First quarter revenues were $244.5 million, up 5% sequentially from Q4 and 21% year-over-year [5][20] - Gross margin for Q1 was 12.4%, an increase of 40 basis points from Q4 but below the forecast of 14.5% [20] - Operating income for Q1 was $6.6 million, with a net interest expense of $1.6 million and a non-GAAP net income tax expense of $600,000 [20] - Free cash flow was $500,000 after generating $19 million in cash flow from operations and deducting $18.5 million in capital expenditures [21] Business Line Data and Key Metrics Changes - The company acknowledged challenges in transitioning from externally supplied products to internally manufactured products, impacting gross margins [6][20] - A new contract in the commercial space market led to higher costs and revenue push-outs due to redesign requirements [9] - The decision to exit the refurbishment business in Scotland had a slight negative impact on both revenue and gross margin [9] Market Data and Key Metrics Changes - The overall customer demand environment has remained consistent, with expectations for modest growth in wafer fab equipment (WFE) for 2025 [5] - The company expects revenue growth to outperform overall WFE growth in 2025 [5] - Specific markets such as silicon carbide applications have weakened, affecting OEM customers differently [14] Company Strategy and Development Direction - The company aims to increase the use of proprietary, internally sourced components to drive gross margin expansion [10] - By the end of 2025, the company expects to have all four major customers qualified on all three major product families: valves, fittings, and substrates [12] - Planned capital expenditures for 2025 are expected to be around 4% of revenue, higher than the historical average of 2% [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for products and qualifications, despite challenges in aligning supply with demand [60] - The company is working to mitigate the impact of tariffs on gross margins and is optimistic about collaboration with customers [42] - Visibility for the second half of the year is less certain, but management believes the business will be relatively evenly weighted between the first and second halves of 2025 [15] Other Important Information - The company is facing complexities due to recent tariff announcements, particularly affecting steel and aluminum imports [12][13] - The exit from the refurbishment business in Scotland was primarily due to declining demand, resulting in a loss of approximately $10 million in annual revenue [96] Q&A Session Summary Question: Change in revenue outlook for the year - Management noted that the lithography business is softer, primarily due to the exit from Scotland, while NAND investment continues [27][29] Question: Gross margins and tariff impacts - Management indicated that they executed about 75% to 80% of their internal sourcing goals, with ongoing improvements expected [32] Question: Customer behavior regarding tariffs - Management stated that customers are collaborating to address tariff impacts, with some costs being passed through [42] Question: Confidence in second half growth - Management expressed confidence in continued strength in DRAM and NAND upgrades, with expectations for growth in the second half [46] Question: Disconnect with largest customer guidance - Management believes there are natural offsets in the market, and they do not see significant disconnects from customer forecasts [54] Question: Impact of exiting Scotland operations - The exit from Scotland was primarily responsible for severance costs, with the majority of the impact coming from that decision [65] Question: Monitoring steps for gross margins - Management acknowledged the need for better forecasting and alignment between supply and demand, with plans for deeper organizational oversight [72] Question: Long-term view on internal sourcing - Management maintains a positive long-term view on incremental margins from internal sourcing, with ongoing improvements expected [82]

Financial Data and Key Metrics Changes - The company reported first quarter product sales of $545 million for INGREZZA, with a reaffirmed sales guidance range for 2025 of $2.5 billion to $2.6 billion, reflecting expected acceleration in new patient additions despite gross to net impacts from contracting activities [8][9][10] - The company has approximately $1.8 billion in cash, supporting its commercial and clinical development strategies for continued growth [11] Business Line Data and Key Metrics Changes - INGREZZA achieved record new patient starts in the first quarter, indicating strong demand and unmet medical needs [9][12] - KRONESITY generated $15 million in net revenue during its first full quarter of launch, with 70% of dispensations receiving reimbursement [10][16] Market Data and Key Metrics Changes - The formulary coverage for INGREZZA in Medicare Part D expanded from less than half to approximately two-thirds, improving patient access [14] - The company noted that 70% of the dispensers for KRONESITY were reimbursed, although most reimbursement was through the exceptions process rather than formal reviews [40] Company Strategy and Development Direction - The company aims to evolve from a single blockbuster to a multiple blockbuster neuroscience company, focusing on both near and long-term revenue growth [5][7] - The R&D portfolio is advancing, with ongoing Phase III studies for osevampatore and MBI-568, and plans to expand the muscarinic portfolio into new Phase II studies later this year [6][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum from record new patient starts and the potential for growth in the second quarter and beyond, despite challenges in the reauthorization process and market dynamics [31][32] - The management team highlighted the importance of continued investment in sales force expansion and marketing initiatives to strengthen INGREZZA's market position [15][16] Other Important Information - The company is transitioning leadership, with Dr. Eiry Roberts moving to a strategic advisory role and Dr. Sanjay Keswani set to become the new Chief Medical Officer [6][25] - The company is focused on increasing awareness and reducing stigma around tardive dyskinesia, collaborating with various organizations to improve patient access to treatment [12][14] Q&A Session Summary Question: Insights on INGREZZA's performance and future growth - Management acknowledged challenges in Q1 but noted record new patient starts, indicating strong momentum going into Q2 and the rest of the year [31][32] Question: Expectations for KRONESITY's adoption and reimbursement dynamics - Management indicated that while initial adoption exceeded expectations, it is too early to define long-term trends, and they will continue to monitor reimbursement patterns [35][40] Question: Share dynamics between INGREZZA and competitors - Management stated that INGREZZA continues to hold a majority share in the tardive dyskinesia market, with ongoing efforts to differentiate from competitors [44] Question: Insights on patient demographics for KRONESITY - Management noted an early trend towards greater uptake in pediatric and adolescent patients compared to adults, aligning with pre-launch expectations [46][69] Question: Contracting strategies and pricing trends for INGREZZA - Management emphasized a focus on maximizing patient access through prudent contracting, with no immediate changes anticipated but ongoing monitoring of the environment [59][82]

Neurocrine Biosciences (NBIX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Todd Tushla - VP, IRKyle Gano - CEOMatt Abernethy - Chief Financial OfficerEric Benevich - Chief Commercial OfficerEiry Roberts - Chief Medical OfficerPaul Matteis - Managing Director, Head of Therapeutics ResearchPhoebe Tan - Senior Biotechnology Equity Research AssociateTazeen Ahmad - MD - US Equity ResearchPhilip Nadeau - MD, Health Care – BiotechnologyBrian Abrahams - MD & Global Sector Head - Health Care R ...